78
Participants
Start Date
October 31, 2007
Primary Completion Date
May 31, 2011
Study Completion Date
May 31, 2011
Idarubicin
12 mg/m\^2 IV over 1 hour daily (days 1-3)
Sorafenib
Starting dose 400 mg by mouth for 7 days
Ara-C
1.5 g/m\^2 IV over 24 hours daily (days 1-4)
The University of Texas M.D. Anderson Cancer Center, Houston
Collaborators (1)
Bayer
INDUSTRY
M.D. Anderson Cancer Center
OTHER